Inograft Biotherapeutics, Inc.

What Inograft Biotherapeutics, Inc. does

Inograft Biotherapeutics is a clinical-stage biotechnology company developing antibody-based, non-genotoxic conditioning regimens for hematopoietic stem cell transplantation (HSCT). The company targets the conditioning phase of HSCT, which currently relies on chemotherapy and radiation regimens that cause significant toxicities including infertility, organ damage, secondary cancers, and treatment-related mortality—barriers that restrict curative transplantation to fewer than 10% of eligible patients despite over one million people in the U.S. alone living with diseases that could potentially be addressed by stem cell transplantation. End-use applications include hematologic cancers, genetic blood disorders, severe autoimmune diseases, and promotion of immune tolerance in solid organ transplantation.

The company's integrated platform comprises three components: a discovery engine using mass spectrometry and RNA sequencing to identify cellular targets required for durable engraftment; a suite of biologic therapies designed to selectively deplete blood-forming stem cells without damaging non-hematopoietic tissues; and predictive preclinical models that mirror human hematopoiesis and immune function to guide molecule selection and dose optimization. The technology originated from Stanford University research led by academic founder Irv Weissman and was previously advanced through Forty Seven Inc. into IND-enabling work and Phase 1 clinical trials, before the program sat at Gilead Sciences following Forty Seven's 2020 acquisition.

Inograft is a privately held, venture-backed pre-revenue company headquartered at 600 Chesapeake Drive, Redwood City, California, with approximately 13 employees. Its go-to-market model is enterprise-oriented, targeting transplant centers, hematology/oncology departments, and healthcare institutions for commercial sales of therapeutic conditioning agents following regulatory approval. The company is financed by ARCH Venture Partners, Sutter Hill Ventures, and Frazier Life Sciences, with leadership drawn heavily from the Forty Seven/Gilead alumni network that previously delivered a $4.9B exit to Gilead in 2020.

Name

Inograft Biotherapeutics, Inc.

Legal name

Inograft Biotherapeutics, Inc.

Website

https://inograft.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Inograft Biotherapeutics is a clinical-stage biotech developing antibody-based, non-genotoxic conditioning therapies to replace chemotherapy and radiation in hematopoietic stem cell transplantation. The Redwood City-based company is backed by ARCH Venture Partners, Sutter Hill Ventures, and Frazier Life Sciences.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO), Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)

Keywords

• Antibody-based therapeutics
• Hematopoietic stem cell transplantation
• Non-genotoxic conditioning
• Biologic conditioning agents
• HSCT conditioning platform

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Therapeutic Product Sales: Pre-revenue clinical-stage biotech company developing antibody-based conditioning therapies for HSCT. Once approved through clinical trials and regulatory pathways, revenue would be generated from commercial sales of therapeutic products to healthcare institutions, transplant centers, and hospitals treating patients with hematologic cancers, genetic blood disorders, and autoimmune diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Inograft Biotherapeutics is developing an integrated antibody-based biologic platform for non-genotoxic conditioning in hematopoietic stem cell transplantation (HSCT). The company's approach combines a discovery engine using mass spectrometry and RNA sequencing to identify cellular targets required for durable engraftment, a suite of targeted biologic conditioning therapies designed to selectively deplete blood-forming stem cells without damaging non-hematopoietic tissues, and predictive preclinical models that mirror human hematopoiesis and immune function. These therapies are intended to replace decades-old chemotherapy- and radiation-based conditioning regimens that cause infertility, organ damage, secondary cancers, and treatment-related mortality.

Product overview

Inograft Biotherapeutics is developing an integrated antibody-based biologic platform for non-genotoxic conditioning in hematopoietic stem cell transplantation (HSCT). The company's approach comprises three integrated components: (1) Target Biology — a discovery engine using mass spectrometry and RNA sequencing to identify cellular targets required for durable engraftment; (2) Selective Engineering — a suite of best-in-class biologic therapies designed to selectively deplete blood-forming stem cells without damage to non-hematopoietic tissues; and (3) Translation to Patients — predictive preclinical models mirroring human hematopoiesis and immune function to guide molecule selection and dose optimization. This platform is purpose-built to enable HSCT with greater precision and safety, replacing traditional chemotherapy and radiation conditioning regimens.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody-Based Non-Genotoxic HSCT Conditioning Platform

Quantifiable outcome

• Current conditioning limits HSCT to fewer than 10% of eligible patients due to toxicities (infertility, organ damage, secondary cancers, treatment-related mortality)
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Gilead SciencesminorOthers · 1 March 2020Gilead Sciences acquired Forty Seven Inc. (prior company founded by same team) in March 2020 for approximately $4.9 billion. The acquisition included the antibody conditioning program for HSCT that the team had advanced from discovery through Phase 1 clinical trials. Following the acquisition, several team members served at Gilead before founding Inograft.
• Stanford University / Stanford Institute for Stem Cell Biology and Regenerative MedicinecoreStrategic or Co-development PartnerAcademic research partnership origin. Technology is rooted in research from Irv Weissman's lab at Stanford University. Founders trained at Stanford, and the company builds on discoveries made at the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Editas Medicine: Editas Medicine develops ex vivo gene-edited HSC therapies (reni-cel for sickle cell) that require HSCT-style conditioning. It competes with Inograft for transplant-center relationships and shapes the addressable population Inograft seeks to expand via safer conditioning.
• CRISPR Therapeutics: CRISPR Therapeutics markets Casgevy, the first FDA-approved CRISPR gene therapy for sickle cell disease and beta-thalassemia, which relies on HSCT-style delivery. As the leading gene-editing incumbent in HSCT-adjacent indications, it is a strategic comparable and potential acquirer or competitor for Inograft's downstream conditioning opportunity.

Emerging players

• Actinium Pharmaceuticals: Actinium's lead asset Iomab-B is a radio-immunotherapy conditioning agent for HSCT in patients with active relapse AML. Like Inograft, it directly competes for conditioning-replacement share within transplant centers, though using a radiation-based rather than pure antibody approach.
• Beam Therapeutics: Beam Therapeutics is developing base-editing therapies for sickle cell disease and beta-thalassemia that depend on HSCT or in vivo editing. It shapes the same end market Inograft targets via conditioning, particularly in non-malignant genetic blood disorders where HSCT uptake is gated by conditioning safety.
• Poseida Therapeutics: Poseida is developing allogeneic CAR-T and HSC gene-editing programs including conditioning-related assets for hematologic disease. Its non-viral genome editing platform intersects with Inograft's HSCT commercialization strategy and targets an overlapping transplant-customer segment.

Others

• Gilead Sciences: Gilead acquired Forty Seven Inc. for $4.9B in 2020, gaining the antibody conditioning program that several Inograft co-founders had led at Forty Seven. As the prior acquirer of the team's conditioning IP, Gilead is a strategic precedent, potential future acquirer, and the dominant incumbent in HSCT-adjacent oncology therapy.
• Allogene Therapeutics: Allogene is developing allogeneic CAR-T cell therapies for hematologic malignancies that depend on lymphodepleting conditioning regimens. As an adjacent cell-therapy platform customer of HSCT-style conditioning, it represents a potential strategic partner and ecosystem comparable in the broader transplant and hematology space.

Direct peers

• Vor Biopharma: Vor Biopharma is engineering hematopoietic stem cells to be resistant to targeted conditioning, enabling post-transplant use of antibody-drug conjugates without harming healthy blood cells. It is highly comparable to Inograft because both companies are addressing the HSCT conditioning bottleneck from complementary angles and competing for the same transplant centers.
• Jasper Therapeutics: Jasper Therapeutics develops antibody-based conditioning agents (anti-CD45, anti-CD117) for HSCT, most directly comparable to Inograft's anti-CD47/stem-cell antibody conditioning platform. Both companies target the same conditioning step with non-genotoxic antibody therapeutics and pursue HSCT for sickle cell, acute myeloid leukemia, and related indications.
• Magenta Therapeutics: Magenta Therapeutics developed antibody-based conditioning agents (anti-CD45, anti-CD117) for HSCT before winding down operations. Although dissolved, it represents the most direct prior comparator to Inograft's conditioning platform and is referenced throughout the transplant community as the standard setter in this niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inograft

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inograft Biotherapeutics, Inc.